Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients

NCT05964361 is registered in ClinicalTrials.gov with University Hospital, Antwerp as lead sponsor.

NCT NCT05964361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05964361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients
Lead sponsor
University Hospital, Antwerp
Phase
Phase 1/2
Overall status
Completed
Start date
December 6, 2023
Completion date
September 22, 2025
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, liver cancer, ovarian cancer, pancreas cancer